Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 4/20 | 0.40 |
| ▸ | CLK1 | P49759 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28015413 | 0.86 | RELA (0.40) | ALDH1A1CYP2A6DYRK1ADYRK1BMAPT | |
| SCHEMBL5136658 | 0.81 | ALDH1A1 (0.43) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| 4-Hydroxybenzaldehyde SCHEMBL6942477 | 0.81 | ALDH5A1 (0.50) | ALDH1A1TDP1RAB9AMAPTMAOB | |
| P-Anisic Acid SCHEMBL3469544 | 0.79 | CA1 (0.56) | ALDH1A1NPC1RAB9ARELAMEN1 | |
| SCHEMBL28168223 | 0.78 | APP (0.49) | ALDH1A1TDP1NPC1RAB9AMAPT | |
| P-Anisic Acid SCHEMBL6586497 | 0.78 | CA1 (0.54) | ALDH1A1NPC1RAB9ARELAMEN1 | |
| 2-Methoxybenzaldehyde SCHEMBL5687915 | 0.77 | ERN1 (0.46) | ALDH1A1TDP1NPC1RAB9ALMNA | |
| 3-Hydroxybenzaldehyde SCHEMBL9842145 | 0.77 | CCNB2 (0.42) | ALDH1A1MAPTMAOBMEN1KMT2A | |
| SCHEMBL9240143 | 0.76 | ALDH1A1 (0.40) | ALDH1A1NPC1RAB9AMAPTLMNA | |
| SCHEMBL27694314 | 0.76 | JAK2 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0674232-B1 | Recording sheets | XEROX CORP (US) | 2000-05-31 | — | — | EP | claimed |
| US-5931995-A | Ink compositions | XEROX CORPORATION (US) | 1999-08-03 | — | — | US | claimed |
| US-5663022-A | Recording sheets | XEROX CORPORATION (US) | 1997-09-02 | — | — | US | claimed |
| EP-0674232-A2 | Recording sheets | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| CN-103242281-A | 3'-hydroxy-4',5,6,7-tetramethoxy isoflavanone and preparation method thereof | UNIV DONGHUA | 2013-08-14 | — | — | CN | disclosed |
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | ZAMBON GROUP S.P.A | 2004-03-04 | — | — | US | disclosed |
| EP-1042300-B1 | PHTHALAZINE DERIVATIVES USEFUL AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON SPA (IT) | 2004-02-11 | — | — | EP | disclosed |
| US-6589951-B1 | N right-arrowO derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF pharmaceutically acceptable salt thereof are PDE 4 and TNF alpha inhibitors. | ZAMBON GROUP S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | COLLIS ALAN JOHN (GB) | 2002-04-25 | — | — | US | disclosed |
| EP-1042300-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2000-10-11 | — | — | EP | disclosed |
| US-6017385-A | Ink compositions | XEROX CORPORATION (US) | 2000-01-25 | — | — | US | disclosed |
| US-5931995-A | Ink compositions | XEROX CORPORATION (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999032456-A1 | PHTHALAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 1999-07-01 | — | — | WO | disclosed |
| EP-0183216-B1 | N-(ARALKOXYBENZYL)-4(BENZHYDRYL) PIPERIDINES | G.D. Searle & Co. (US) | 1989-07-19 | — | — | EP | disclosed |
| US-4650874-A | CARDIOVASCULAR AGENTS | G. D. SEARLE & CO. (US) | 1987-03-17 | — | — | US | disclosed |
| EP-0183216-A1 | N-(Aralkoxybenzyl)-4(benzhydryl) piperidines | G.D. Searle & Co. (US) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049322-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, IDH3B | ALDH1A1 514/4885CYP2A6 236/4885TDP1 2296/4885 |
| US-20040043999-A1 | Phthalazine derivatives as phosphodiesterase 4-inhibitors | PDE5A, PDE3B, PDE3A | ALDH1A1 780/4885CYP2A6 430/4885TDP1 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.